Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 5/20 | 0.45 |
| ▸ | RXRA | P19793 | 3/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22402421 | 0.86 | HTR3A (0.46) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL906097 | 0.86 | HTR2C (0.52) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL22391929 | 0.85 | HTR3A (0.45) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL27621036 | 0.85 | HTR2C (0.51) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6783430 | 0.83 | HTR3A (0.47) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL905754 | 0.82 | HTR2C (0.50) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL905816 | 0.82 | HTR2C (0.44) | HTR2CHTR2AHTR2BSLC6A4 | |
| SCHEMBL905815 | 0.82 | HTR2C (0.44) | HTR2CHTR2AHTR2BSLC6A4 | |
| SCHEMBL6785522 | 0.81 | HTR3E (0.46) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL906027 | 0.81 | HTR2C (0.64) | HTR3AHTR2CHTR2AHTR2BCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-03-10 | — | — | US | claimed |
| US-6825198-B2 | FOR THERAPY OF SEXUAL DISORDER | PFIZER INC | 2004-11-30 | — | — | US | claimed |
| EP-1401819-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-06-05 | — | — | US | claimed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| US-6995159-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-03-10 | — | — | US | disclosed |
| US-20050032809-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-02-10 | — | — | US | disclosed |
| US-6825198-B2 | FOR THERAPY OF SEXUAL DISORDER | PFIZER INC | 2004-11-30 | — | — | US | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1401819-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-06-05 | — | — | US | disclosed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032809-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | HTR3A 6/4885HTR3E 16/4885HTR3B 10/4885 |
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR3A 7/4885HTR3E 13/4885HTR3B 5/4885 |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | HTR3A 5/4885HTR3E 17/4885HTR3B 12/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR3A 7/4885HTR3E 13/4885HTR3B 5/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR3A 7/4885HTR3E 13/4885HTR3B 5/4885 |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | HTR3A 6/4885HTR3E 16/4885HTR3B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.